secwatch.observer — SEC 8-K summary
======================================

Issuer:     Absci Corp (ABSI)
CIK:        0001672688
Form:       8-K
Filed at:   2023-12-07T23:59:59+00:00
Accession:  0001628280-23-040988
Event type: leadership
Sentiment:  neutral
Materiality: 0.45
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Absci appoints Sir Menelas Pangalos (AstraZeneca EVP) to Board, effective Jan 1, 2024
--------------------------------------------------------------------------------

- Board size fixed at 7 directors; Pangalos appointed as Class II director until 2026 annual meeting.
- Initial option grant to purchase 106,200 shares, vesting monthly over 3 years from Grant Date.
- Annual cash retainer of $47,500 for Board and Compensation Committee service.
- Sir Pangalos currently serves as Executive Vice-President, R&D BioPharmaceuticals at AstraZeneca.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1672688/000162828023040988/0001628280-23-040988-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1672688/000162828023040988/absc-20231205.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-040988

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer